Eli Lilly, Boehringer say EMA accepts for review MAA for empagliflozin

Boehringer Ingelheim and Eli Lilly and Company announced the European Medicines Agency has accepted for review a marketing authorization application for the investigational sodium glucose co-transporter-2 inhibitor empagliflozin, for the treatment of type 2 diabetes mellitus in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment. A New Drug Application for empagliflozin was recently submitted to the Food and Drug Administration in the United States for the treatment of T2D in adults. Empagliflozin is a member of the SGLT2 inhibitor class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. The emerging SGLT2 inhibitor class removes excess glucose through the urine by blocking glucose re-absorption in the kidney.